Log in to search using one of your social media accounts:

 

Laser May Be Safer Than Bevacizumab in Babies With Acute-phase ROP Laser May Be Safer Than Bevacizumab in Babies With Acute-phase ROP
Babies with acute-phase retinopathy of prematurity (ROP) who are treated with bevacizumab have more long-term eye problems than babies treated with laser, according to a new randomized controlled trial done in Italy.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 18, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Amgen and Allergan ’s anti-cancer biosimilar Mvasi receives FDA approval
The US Food and Drug Administration (FDA) has approved Mvasi (bevacizumab-awwb) for the treatment of five types of cancer. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 17, 2017 Category: Pharmaceuticals Source Type: news

FDA has approved biosimilar of Roche's Avastin
Amgen Inc. AMGN, -1.37% and Allergan AGN, -1.08% said Thursday that the Food and Drug Administration has approved their biosimilar version of Roche's Avastin for five types of cancer.09/15/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 15, 2017 Category: Urology & Nephrology Source Type: news

Mvasi Is First Biosimilar Drug Approved for Cancer
Similar to Avastin (Source: Cancercompass News: Other Cancer)
Source: Cancercompass News: Other Cancer - September 15, 2017 Category: Cancer & Oncology Source Type: news

FDA Approves First Biosimilar Drug for Cancer
Mvasi (bevacizumab - awwb) is biosimilar to Avastin (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 15, 2017 Category: Cancer & Oncology Tags: Gastroenterology, Gynecology, Internal Medicine, Nephrology, Oncology, Pharmacy, Pulmonology, Institutional, Source Type: news

Mvasi Is First Biosimilar Drug Approved for Cancer
Similar to Avastin (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 14, 2017 Category: Cancer & Oncology Tags: Oncology, Pharmacy, FDA Approvals, Source Type: news

FDA Approves Mvasi (bevacizumab-awwb), a Biosimilar to Avastin
September 14, 2017 -- The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvasi is the first biosimilar approved in the U.S. for the... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 14, 2017 Category: Drugs & Pharmacology Source Type: news

FDA Approves Amgen And Allergan's MVASI ™ (bevacizumab-awwb) For The Treatment Of Five Types Of Cancer
Approval Based on Totality of Evidence From Global Development Program Showing MVASI™ is Highly Similar to Avastin® (bevacizumab) First Ever Biosimilar to Fight Cancer Approved by FDA THOUSAND OAKS, Calif., Sept. 14, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Allergan plc. (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved MVASI™ (bevacizumab-awwb) for all eligible indications of the reference product, Avastin® (bevacizumab). MVASI is the first anti-cancer biosimilar, as well as the first bevacizumab biosimilar, approved by the FDA. MVASI i...
Source: Amgen News Release - September 14, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

First Oncology Biosimilar Approved in US: Bevacizumab First Oncology Biosimilar Approved in US: Bevacizumab
The FDA has approved the first biosimilar for use in the treatment of cancer: Myasi, or bevacizumab-awwb (equivalent to Avastin).News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 14, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

Mvasi Is First Biosimilar Drug Approved for Cancer
THURSDAY, Sept. 14, 2017 -- The first biosimilar drug to treat cancer has been approved by the U.S. Food and Drug Administration. Mvasi (bevacizumab-awwb) was found to be biosimilar to the anti-cancer drug Avastin, the FDA said Thursday in a news... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 14, 2017 Category: General Medicine Source Type: news

U.S. FDA approves biosimilar version of cancer drug Avastin
(Reuters) - The U.S. Food and Drug Administration said on Thursday it has approved Amgen Inc's biosimilar version of Roche Holding AG's cancer drug Avastin. (Source: Reuters: Health)
Source: Reuters: Health - September 14, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Avastin Clone OK'd
(MedPage Today) -- Biosimilar for bevacizumab approved for various cancers (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - September 14, 2017 Category: American Health Source Type: news

FDA approves first biosimilar for the treatment of cancer
The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvasi is the first biosimilar approved in the U.S. for the treatment of cancer. (Source: Food and Drug Administration)
Source: Food and Drug Administration - September 14, 2017 Category: American Health Source Type: news

FDA OKs First'Biosimilar' Drug to Fight Cancer, Mvasi
THURSDAY, Sept. 14, 2017 -- The first approval of a biosimilar drug to treat cancer was announced Thursday by the U.S. Food and Drug Administration. Mvasi (bevacizumab-awwb) was approved as a biosimilar to Avastin (bevacizumab) for the treatment of... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 14, 2017 Category: General Medicine Source Type: news

FDA approves first biosimilar for the treatment of cancer
The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvasi is the first biosimilar approved in the U.S. for the treatment of cancer. (Source: World Pharma News)
Source: World Pharma News - September 14, 2017 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

New technique gives a clearer image of immunotherapy results in advanced brain cancer
FINDINGSResearchers led by Robert Prins, a member of the UCLA Jonsson Comprehensive Cancer Center, have developed a new approach for brain imaging that can better distinguish immune responses from tumor growth in both preclinical studies and in people with glioblastoma.BACKGROUNDDespite clinical advances in immunotherapy for cancer, non-invasive monitoring of tumor growth (especially in people with brain tumors) has been a significant problem. When clinicians use traditional medical imaging processes, the inflammation that sometimes results from immunotherapies can resemble neurological decline and tumor growth.METHODPrins...
Source: UCLA Newsroom: Health Sciences - September 5, 2017 Category: Universities & Medical Training Source Type: news

Is Syringe Lubricant Causing Floaters After Eye Injection?
(MedPage Today) -- Complaints after bevacizumab injections may be due to syringe design (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - August 15, 2017 Category: General Medicine Source Type: news

Ophthotech eye-drug trial fails to meet primary endpoint
Shares in Ophthotech (NSDQ:OPHT) dipped to $2.46 apiece this morning after the company announced that its Phase III wet age-related macular degeneration trial failed to meet its primary endpoint. The New York-based company said that the addition of Fovista (pegpleranib) to Eylea or Avastin, both anti-VEGF therapies, did not significantly improve visual acuity after 12-months compared to Eylea or Avastin alone. Get the full story at our sister site, Drug Delivery Business News. The post Ophthotech eye-drug trial fails to meet primary endpoint appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - August 14, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Optical/Ophthalmic Pharmaceuticals Wall Street Beat ophthotech Source Type: news

Adding Bevacizumab to Chemo Boosts Survival in Advanced Cervical Cancer Adding Bevacizumab to Chemo Boosts Survival in Advanced Cervical Cancer
The overall survival (OS) benefit seen with bevacizumab in advanced cervical cancer persists with extended follow-up, new research shows.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 7, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Pfizer announces positive top-line results from the comparative REFLECTIONS B7391003 study for PF-06439535, a potential biosimilar to Avastin ® (bevacizumab)
Pfizer Inc. (NYSE:PFE) has announced that the REFLECTIONS B7391003 study, a comparative, confirmatory safety and efficacy study of PF-06439535 versus Avastin®(1) (bevacizumab), met its primary objective. PF-06439535 is being developed by Pfizer as a potential biosimilar to Avastin. (Source: World Pharma News)
Source: World Pharma News - July 25, 2017 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Biosimilars to Avastin and Herceptin Head for US Market Biosimilars to Avastin and Herceptin Head for US Market
Two new biosimilars, bevacizumab and trastuzumab, were unanimously recommended for approval by an FDA oncologic advisory committee.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 14, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Biosimilars Get Clean Sweep at FDA Hearings
(MedPage Today) -- Unanimous backing for Herceptin biosimilar; follows identical vote for Avastin copy (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - July 13, 2017 Category: American Health Source Type: news

ODAC Gives Thumbs Up to Avastin Biosimilar
(MedPage Today) -- Unanimous recommendation for FDA approval (Source: MedPage Today Urology)
Source: MedPage Today Urology - July 13, 2017 Category: Urology & Nephrology Source Type: news

Amgen And Allergan To Discuss Data Supporting Biologics License Application For ABP 215, A Biosimilar Candidate To Avastin ® (bevacizumab)
First Amgen and Allergan Oncology Biosimilar Candidate to be Reviewed by U.S. FDA Advisory Committee THOUSAND OAKS, Calif., July 13, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced that the Companies will discuss data supporting the ABP 215 Biologics License Application (BLA) with the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA). ABP 215 is a biosimilar candidate to Avastin® (bevacizumab) and is the first bevacizumab biosimilar candidate to be considered by the FDA. "Amgen has worked diligently to apply our more tha...
Source: Amgen News Release - July 13, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Intravitreal Bevacizumab Via Insulin Syringe Tied to Oil Droplets Intravitreal Bevacizumab Via Insulin Syringe Tied to Oil Droplets
Bevacizumab prepared in insulin syringes is associated with an increase in intravitreal silicone oil droplets in patients using the medication, as well as a higher risk of floaters, researchers in California say.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 26, 2017 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Bevacizumab Fails to Improve Survival in Resected High-Risk Melanoma
Treatment with single-agent bevacizumab resulted in an improved disease-free interval in patients with resected melanoma, but no increase in overall survival compared with observation. (Source: CancerNetwork)
Source: CancerNetwork - June 25, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Melanoma News Source Type: news

Similar Efficacy for Key Anti-VEGF Agents in Macular Edema Similar Efficacy for Key Anti-VEGF Agents in Macular Edema
The SCORE2 trial shows that bevacizumab and aflibercept may produce similar short-term outcomes. Here is a closer look at its results.Medscape Optometry (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 20, 2017 Category: Consumer Health News Tags: Ophthalmology Viewpoint Source Type: news

Aflibercept May Be Effective for Resistant Exudative AMD Aflibercept May Be Effective for Resistant Exudative AMD
Aflibercept appears to improve outcomes in patients with exudative age-related macular degeneration (AMD) resistant to treatment with ranibizumab or bevacizumab, researchers from Norway report.Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - June 14, 2017 Category: Opthalmology Tags: Ophthalmology News Source Type: news

MassDevice.com +5 | The top 5 medtech stories for June 8, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. Sanuwave Health inks dev deal with eKare for wound care integration Sanuwave Health said today it entered a memorandum of understanding with eKare to develop novel wound care analysis and management solutions which integrates t...
Source: Mass Device - June 8, 2017 Category: Medical Devices Authors: MassDevice Tags: News Well Plus 5 Source Type: news

Novocure launches Optune, chemotherapy combo trial for glioblastoma
Novocure (NSDQ:NVCR) said today that the 1st patient was enrolled in a Phase II pilot trial evaluating Optune with bevacizumab, a chemotherapy, for patients with refractory recurrent glioblastoma. In recurrent GBM, Optune and bevacizumab are approved as monotherapies. Novocure’s consortium study is slated to evaluate the efficacy and safety of the Optune-chemo combo in patients with bevacizumab-refractory recurrent GBM. Get the full story at our sister site, Drug Delivery Business News. The post Novocure launches Optune, chemotherapy combo trial for glioblastoma appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - June 8, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Neurological Oncology Pharmaceuticals Wall Street Beat NovoCure Source Type: news

Atezolizumab/Bevacizumab in Metastatic RCC Moves to Phase III Trial
This video reviews second-line data from the IMmotion150 trial, which initially studied atezolizumab with or without bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma patients. (Source: CancerNetwork)
Source: CancerNetwork - June 8, 2017 Category: Cancer & Oncology Authors: Michael B. Atkins, MD Tags: Conferences/ASCO Renal Cell Carcinoma News Videos Genitourinary Cancers Source Type: news

Amgen And Allergan Announce FDA Advisory Committee Meeting To Review ABP 215, A Biosimilar Candidate To Bevacizumab
THOUSAND OAKS, Calif., June 7, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE: AGN) today announced that the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will review data supporting the Biologics License Application (BLA) for ABP 215, a biosimilar candidate to Avastin® (bevacizumab), on July 13, 2017. "Amgen has a long and proud heritage in oncology, and we are committed to providing physicians and patients a range of high quality therapeutic options," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "...
Source: Amgen News Release - June 7, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Bevacizumab Improves Responses, PFS in Advanced Head and Neck Cancer
This video highlights results of a phase III randomized trial that tested chemotherapy plus bevacizumab in patients with recurrent or metastatic head and neck cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 6, 2017 Category: Cancer & Oncology Authors: Barbara Burtness, MD Tags: Conferences/ASCO Street Team Head & Neck Cancer News Source Type: news

Bevacizumab Does Not Improve Response, Survival in Ovarian Cancer
Adding bevacizumab to neoadjuvant chemotherapy did not improve complete macroscopic response rate or progression-free survival in women with ovarian cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 3, 2017 Category: Cancer & Oncology Authors: Bryant Furlow Tags: Conferences/ASCO Ovarian Cancer News Source Type: news

Minimal Differences Between Anti-VEGF Drugs on IOP Over Time Minimal Differences Between Anti-VEGF Drugs on IOP Over Time
Patients on anti-VEGF therapy may have a small decrease in intraocular pressure (IOP) over time, but with minimal differences between aflibercept, ranibizumab, and bevacizumab, a new large study suggests.Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - June 1, 2017 Category: Opthalmology Tags: Ophthalmology News Source Type: news

Bevacizumab Effective for Macular Edema Due to Central Retinal Vein Occlusion Bevacizumab Effective for Macular Edema Due to Central Retinal Vein Occlusion
Bevacizumab is as effective as aflibercept for improving visual acuity in patients with macular edema due to central retinal vein occlusion, according to results from the SCORE2 trial.Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - May 18, 2017 Category: Opthalmology Tags: Ophthalmology News Source Type: news

Avastin as effective as Eylea for treating central retinal vein occlusion
Monthly eye injections of Avastin (bevacizumab) are as effective as the more expensive drug Eylea (aflibercept) for the treatment of central retinal vein occlusion (CRVO), according to a clinical trial funded by the National Eye Institute (NEI), part of the National Institutes of Health. After six monthly injections, treatment with either drug improved visual acuity on average from 20/100 to  20/40. (Source: News from NEI)
Source: News from NEI - May 10, 2017 Category: Opthalmology Authors: haysdc Source Type: news

Bevacizumab On Par With Aflibercept in Retinal Vein Occlusion (CME/CE)
(MedPage Today) -- Outcomes similar with both anti-VEGF agents (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - May 10, 2017 Category: Consumer Health News Source Type: news

Avastin as effective as Eylea for treating central retinal vein occlusion
Monthly eye injections of Avastin (bevacizumab) are as effective as the more expensive drug Eylea (aflibercept) for the treatment of central retinal vein occlusion (CRVO), according to a clinical trial. After six monthly injections, treatment with either drug improved visual acuity on average from 20/100 to 20/40. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 9, 2017 Category: Science Source Type: news

Avastin as effective as Eylea for treating central retinal vein occlusion
NIH-funded clinical trial shows use of either drug improved vision and had few side effects. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - May 9, 2017 Category: American Health Source Type: news

NovoCure launches 2 pediatric trials of TTFields
NovoCure (NSDQ:NVCR) said today it is launching 2 pilot trials exploring the use of tumor treating fields to treat pediatric patients with high grade gliomas. The St. Helier, N.J.-based company produces the Optune, a mobile device that delivers low-intensity, intermediate frequency, alternating electric fields, referred to as “tumor treating fields” to inhibit cancer cell replication and cause cancer cell death. The 1st trial is being sponsored by the Pediatric Brain Tumor Consortium in collaboration with the National Cancer Institute and will study the feasibility of using TTFields on children w...
Source: Mass Device - May 4, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Clinical Trials Oncology NovoCure Source Type: news

PET/CT helps predict therapy effectiveness in pediatric brain tumors
(Society of Nuclear Medicine) In this first ever molecular drug-imaging study in children, researchers in The Netherlands used whole-body positron emission tomography/computed tomography (PET/CT) scans to determine whether bevacizumab (Avastin) treatment of diffuse intrinsic pontine glioma (DIPG) in children is likely to be effective. The study is featured in the May 2017 issue of The Journal of Nuclear Medicine. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 2, 2017 Category: Global & Universal Source Type: news

Texas Researchers Summarize Promising Research on New Mesothelioma...
The authors of a new report on bevacizumab (Avastin) say there continues to be good evidence that the VEGF-inhibitor can boost the effectiveness of mesothelioma chemotherapy.(PRWeb May 02, 2017)Read the full story at http://www.prweb.com/releases/2017/05/prweb14296837.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - May 2, 2017 Category: Pharmaceuticals Source Type: news

Repeated Intravitreal Injections Linked to Glaucoma (CME/CE)
(MedPage Today) -- 7 or more bevacizumab injections per year may double risk of glaucoma surgery (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - May 1, 2017 Category: Consumer Health News Source Type: news

Bevacizumab Fails to Boost SCLC Survival (CME/CE)
(MedPage Today) -- PFS but not OS improved by angiogenesis inhibitor (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 26, 2017 Category: Hematology Source Type: news

Repeated Bevacizumab Injections Tied to Higher Glaucoma Surgery Risk Repeated Bevacizumab Injections Tied to Higher Glaucoma Surgery Risk
Seven or more intravitreous bevacizumab injections in a year is associated with a higher risk of glaucoma surgery, researchers in Canada say.Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - March 23, 2017 Category: Opthalmology Tags: Ophthalmology News Source Type: news

Repeated eye injections for age-related macular degeneration associated with increased risk for glaucoma
Patients with age-related macular degeneration who received seven or more eye injections of the drug bevacizumab annually had a higher risk of having glaucoma surgery, according to a study. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 16, 2017 Category: Science Source Type: news

More Bevacizumab Shots for AMD May Up Risk of Glaucoma
(MedPage Today) -- Repeated injections tied to increased ocular pressure, higher rates of surgery (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - March 16, 2017 Category: Geriatrics Source Type: news

Frontline Immunotherapy/Bevacizumab Ups PFS in PD-L1-Positive mRCC
This video examines a phase II study that compared atezolizumab with or without bevacizumab vs sunitinib in untreated patients with metastatic renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - March 3, 2017 Category: Cancer & Oncology Authors: David F. McDermott, MD Tags: Videos Genitourinary Cancers Source Type: news